Cytochrome P450 in Pharmacogenetics: An Update

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Kuvaus

Interindividual variability in drug disposition is a major cause of lack of efficacy and adverse effects of drug therapies. The majority of hepatically cleared drugs are metabolized by cytochrome P450 (CYP) enzymes, mainly in families CYP1, CYP2, and CYP3. Genes encoding these enzymes are highly variable with allele distribution showing considerable differences between populations. Genetic variability of especially CYP2C9, CYP2C19, CYP2D6, and CYP3A5 is known to have clear clinical impact on drugs that are metabolized by these enzymes. CYP1A2, CYP2A6, CYP2B6, CYP2C8, and CYP3A4 all show variability that affects pharmacokinetics of drugs as well, but so far the evidence regarding their clinical implications is not as conclusive. In this review, we provide an up-to-date summary of the pharmacogenetics of the major human drug-metabolizing CYP enzymes, focusing on clinically significant examples. © 2018 Elsevier Inc.
Alkuperäiskielienglanti
LehtiAdvances in Pharmacology
Vuosikerta83
Sivut3-32
Sivumäärä30
ISSN1054-3589
DOI - pysyväislinkit
TilaJulkaistu - 2018
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Lisätietoja

cited By 1

Tieteenalat

  • 317 Farmasia

Lainaa tätä

@article{7f069c13084c49c4b7105159d6adf1a4,
title = "Cytochrome P450 in Pharmacogenetics: An Update",
abstract = "Interindividual variability in drug disposition is a major cause of lack of efficacy and adverse effects of drug therapies. The majority of hepatically cleared drugs are metabolized by cytochrome P450 (CYP) enzymes, mainly in families CYP1, CYP2, and CYP3. Genes encoding these enzymes are highly variable with allele distribution showing considerable differences between populations. Genetic variability of especially CYP2C9, CYP2C19, CYP2D6, and CYP3A5 is known to have clear clinical impact on drugs that are metabolized by these enzymes. CYP1A2, CYP2A6, CYP2B6, CYP2C8, and CYP3A4 all show variability that affects pharmacokinetics of drugs as well, but so far the evidence regarding their clinical implications is not as conclusive. In this review, we provide an up-to-date summary of the pharmacogenetics of the major human drug-metabolizing CYP enzymes, focusing on clinically significant examples. {\circledC} 2018 Elsevier Inc.",
keywords = "317 Pharmacy",
author = "A. Tornio and J.T. Backman",
note = "cited By 1",
year = "2018",
doi = "10.1016/bs.apha.2018.04.007",
language = "English",
volume = "83",
pages = "3--32",
journal = "Advances in Pharmacology",
issn = "1054-3589",
publisher = "Academic Press Inc.",

}

Cytochrome P450 in Pharmacogenetics: An Update. / Tornio, A.; Backman, J.T.

julkaisussa: Advances in Pharmacology, Vuosikerta 83, 2018, s. 3-32.

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

TY - JOUR

T1 - Cytochrome P450 in Pharmacogenetics: An Update

AU - Tornio, A.

AU - Backman, J.T.

N1 - cited By 1

PY - 2018

Y1 - 2018

N2 - Interindividual variability in drug disposition is a major cause of lack of efficacy and adverse effects of drug therapies. The majority of hepatically cleared drugs are metabolized by cytochrome P450 (CYP) enzymes, mainly in families CYP1, CYP2, and CYP3. Genes encoding these enzymes are highly variable with allele distribution showing considerable differences between populations. Genetic variability of especially CYP2C9, CYP2C19, CYP2D6, and CYP3A5 is known to have clear clinical impact on drugs that are metabolized by these enzymes. CYP1A2, CYP2A6, CYP2B6, CYP2C8, and CYP3A4 all show variability that affects pharmacokinetics of drugs as well, but so far the evidence regarding their clinical implications is not as conclusive. In this review, we provide an up-to-date summary of the pharmacogenetics of the major human drug-metabolizing CYP enzymes, focusing on clinically significant examples. © 2018 Elsevier Inc.

AB - Interindividual variability in drug disposition is a major cause of lack of efficacy and adverse effects of drug therapies. The majority of hepatically cleared drugs are metabolized by cytochrome P450 (CYP) enzymes, mainly in families CYP1, CYP2, and CYP3. Genes encoding these enzymes are highly variable with allele distribution showing considerable differences between populations. Genetic variability of especially CYP2C9, CYP2C19, CYP2D6, and CYP3A5 is known to have clear clinical impact on drugs that are metabolized by these enzymes. CYP1A2, CYP2A6, CYP2B6, CYP2C8, and CYP3A4 all show variability that affects pharmacokinetics of drugs as well, but so far the evidence regarding their clinical implications is not as conclusive. In this review, we provide an up-to-date summary of the pharmacogenetics of the major human drug-metabolizing CYP enzymes, focusing on clinically significant examples. © 2018 Elsevier Inc.

KW - 317 Pharmacy

U2 - 10.1016/bs.apha.2018.04.007

DO - 10.1016/bs.apha.2018.04.007

M3 - Article

VL - 83

SP - 3

EP - 32

JO - Advances in Pharmacology

JF - Advances in Pharmacology

SN - 1054-3589

ER -